Home » Newsletters » BioWorld Science

BioWorld Science

June 20, 2003

View Archived Issues

CTI-01 enters dose-escalating phase I trial

Enzo Biochem's new Crohn's disease therapy enters phase II

Preclinical characterization of A-348441, a liver-selective GR antagonist for type 2 diabetes

Long-lasting antidiabetic action of Albugon in animals

Transmucosal insulin exerts sustained hypoglycemic effects in normal and diabetic rats

Reduced nasal obstructive response to allergen after pretreatment with CAT-213

Fidarestat safe and effective in diabetic polyneuropathy

Korean researchers design RNA-binding neomycin-chloramphenicol conjugates

Iconix presents Rho C inhibitors with utility in cancer therapy

Novel PPAR modulators under study at Ono

Inhibitors of Arg- and Lys-gingipain and their use in periodontitis therapy

Lilly prepares and tests new beta3-adrenoceptors agonists

Sanofi-Synthelabo claims three series of alpha7-selective nAChR ligands

New ERbeta agonists for use in prostate cancer covered by Lilly patent

Phase II IND cleared for oral phenoxodiol

Arava cleared for improving physical function in rheumatoid arthritis patients

Astex discovers novel form of PTP1B

CeNeS and Elan terminate joint venture

Amarin to provide formulation and manufacturing services to Acadia

NNC-1049 decreases food intake and body weight in obese rats

Dual PPARgamma/alpha agonist improves both glucose and lipid profiles in ZDF rats

Beneficial effects of RXR agonist on glucose, insulin and lipid profiles in animal models

Indevus announces phase II trial with PRO-2000 to prevent sexual transmission of HIV

Encouraging preclinical results reported for CytoGenix anti-HSV drug

Bayer and PPL place hold on recombinant alpha1-antitrypsin development project

Encysive receives SPA from the FDA for sitaxsentan

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...